Almaden Releases g.nome™ with Jupyter Notebook Integration
PharmiWeb - April 2023
DALLAS (April 2023) – Almaden Genomics has updated its g.nome™ platform to integrate with Jupyter Notebook, an open-source web-based environment that is commonly used for collaborative research. The software combination will further enable scientists and bioinformaticians to accelerate genomic discovery by leveraging g.nome’s cloud-native and intuitive NGS workflow builder with a widely used data visualization tool.
“We built g.nome to make the computational biologist’s job both innovative and familiar,” said Mark Kunitomi, Chief Scientific Officer of Almaden Genomics. “With this integration, you can build and run a workflow in g.nome, then seamlessly utilize that data output for visualization in Jupyter Notebooks. This comfortably expands the capabilities of the researcher, who is more than likely accustomed to this type of integration already.”
Bioinformaticians and data scientists across various disciplines use Jupyter Notebook to record notes and interpret their analyses in a fully customizable format. Supported by reciprocal file sharing, this integration adds data visualization capability via g.nome, compounding the platform’s possibilities and making iteration even easier for the user. After building and running secondary NGS data analysis workflows in g.nome, users now have the ability to interpret that data in a meaningful way, then use those learnings to either adjust their workflow or influence further genomic discovery – completely uninterrupted by tedious manual downloads and uploads.
At most biotech firms and research institutes, genomic workflows are still being laboriously hand-coded by a limited number of highly skilled bioinformaticians. Almaden’s g.nome platform provides an entirely new option for research teams desiring a more collaborative environment. With a drag-and-drop GUI as well as a library of pre-built workflows and open-source tools, g.nome enables scientists of every skill level to actively participate in the pipeline building and executing processes.
“Our goal is to accelerate discovery by removing unnecessary barriers, and this integration supports that mission by allowing researchers to seamlessly process and visualize the data that is integral to advancing modern medicine using an interactive computing platform used for visualizations, scientific computing and machine learning,” said David Gascoigne who joined Almaden as CEO earlier this year, bringing with him a deep understanding of integrated data sets and machine learning in the health sciences space.
About Almaden Genomics
Almaden Genomics is accelerating genomic discovery with g.nome™, a cloud-native data analysis platform designed to streamline genomic workflows. Brought to market by a team of bioinformaticians, engineers and industry professionals, g.nome provides a low-code/no-code pipeline build, enabling valuable collaboration from diverse team members with an easy-to-use, visual drag-and-drop functionality using built-in tools and features, such as ready-to-use workflows and a curated toolkit library. Formerly part of IBM Research, Almaden Genomics became a new standalone company under Catalyze Dallas’ ownership in 2022. For more information, visit www.almaden.io.
Visualization generated by open-source code from Gos.